Wall Street brokerages expect IntriCon Co. (NASDAQ:IIN) to report earnings of $0.10 per share for the current quarter, according to Zacks. Two analysts have made estimates for IntriCon’s earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $0.12. IntriCon reported earnings per share of $0.25 in the same quarter last year, which would suggest a negative year over year growth rate of 60%. The firm is expected to issue its next quarterly earnings results on Wednesday, July 24th.
On average, analysts expect that IntriCon will report full year earnings of $0.63 per share for the current fiscal year, with EPS estimates ranging from $0.62 to $0.63. For the next financial year, analysts expect that the company will post earnings of $1.22 per share, with EPS estimates ranging from $1.00 to $1.65. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow IntriCon.
IntriCon (NASDAQ:IIN) last released its quarterly earnings results on Monday, April 29th. The technology company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.02). The company had revenue of $30.11 million for the quarter, compared to the consensus estimate of $30.05 million. IntriCon had a return on equity of 8.02% and a net margin of 4.58%.
Several analysts recently weighed in on the company. ValuEngine upgraded IntriCon from a “hold” rating to a “buy” rating in a research note on Tuesday, May 7th. Zacks Investment Research downgraded IntriCon from a “hold” rating to a “sell” rating in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $50.25.
In other IntriCon news, VP Greg Gruenhagen sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $25.33, for a total value of $37,995.00. Following the completion of the sale, the vice president now owns 4,047 shares in the company, valued at approximately $102,510.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.50% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in IIN. BNP Paribas Arbitrage SA acquired a new position in shares of IntriCon in the 1st quarter worth approximately $40,000. MetLife Investment Advisors LLC acquired a new position in shares of IntriCon in the 3rd quarter worth approximately $295,000. Sun Life Financial INC acquired a new position in shares of IntriCon in the 4th quarter worth approximately $155,000. Rhumbline Advisers raised its holdings in shares of IntriCon by 58.9% in the 4th quarter. Rhumbline Advisers now owns 9,104 shares of the technology company’s stock worth $240,000 after buying an additional 3,375 shares in the last quarter. Finally, Conestoga Capital Advisors LLC acquired a new position in shares of IntriCon in the 1st quarter worth approximately $235,000. Institutional investors own 66.85% of the company’s stock.
NASDAQ:IIN traded up $0.47 during mid-day trading on Wednesday, hitting $25.51. 61,819 shares of the company’s stock traded hands, compared to its average volume of 165,560. IntriCon has a 12 month low of $20.95 and a 12 month high of $76.80. The company has a market cap of $218.85 million, a price-to-earnings ratio of 39.86, a PEG ratio of 3.22 and a beta of 1.15.
IntriCon Company Profile
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.
Further Reading: How much can an individual set aside as a catch-up contribution?
Get a free copy of the Zacks research report on IntriCon (IIN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.